Repligen | RGEN - PE价格收益



金融业
股票价格
USD
资产
USD 2.95B
现金及等价物
USD 566.02M
销售成本
USD 94.08M
流动资产
USD 1.14B
流动负债
USD 135.83M
债务
USD 542.21M
EBIT
USD 19.97M
EBITDA
USD 39.54M
员工
1.78K
EPS每股收益
USD 0.49
股本和储备
USD 2.11B
销售毛利
USD 103.83M
债务利息支出
USD 5.5M
利息收入
USD 7.31M
贷款资金
USD 542.21M
市值
USD 6.42B
净收入
USD 13.29M
营业费用
USD 177.95M
营业利润
USD 19.97M
普通股股本
USD 56.33M
PE价格收益
164.06
税前利润
USD 17.11M
销售收入
USD 197.91M
销售和管理费用
USD 74.36M
股票
USD 170.46M
贸易债权人
USD 30.01M
应收帐款人
USD 158.59M


Pe 更改 日
Agilent 25.04 2.13 2025-12
Align Technology 19.74 1.58 2025-12
Bio Techne 38.5 3.96 2025-09
BioMarin Pharmaceutical 19.24 0.21 2025-12
Bristol-Myers Squibb 9.28 1.04 2025-12
Bruker 81.36 60.11 2025-12
Charles River Laboratories 43.58 0.86 2025-12
Danaher 39.67 4.06 2025-12
Dentsply International 29.99 15.81 2025-12
General Electric Aerospace 39.22 0.59 2025-12
Henry Schein 18.42 2.8 2025-12
Illumina 30.38 15.53 2025-12
IQVIA Holdings 26.59 2.03 2025-12
Mettler Toledo International 32.41 2.38 2025-12
OraSure Technologies 24.42 12.6 2024-09
Pacific Biosciences Of California 681.32 681.02 2020-12
Pfizer 14.48 5.18 2025-12
Repligen 164.06 23.88 2025-12
Revvity 49.87 16.58 2025-12
Thermo Fisher Scientific 31 6.22 2025-12
Waters 35.29 8.46 2025-12
West Pharmaceutical Services 37.75 0.22 2025-12